If you cheat, money will follow

Jiangzhou.

Pingtou Ge Research Institute.

"Boss, 20 pharmaceutical companies jointly reported to us..." Zeng Xi came to Chang Le's office:

"They found a large number of traces of infringement in Huirui's new anti-epidemic drug. It infringed on at least 8 of our patents."

"They want us to file a lawsuit against Huirui over this."

"Patent infringement? So blatant?" Chang Le was surprised:

"No wonder it's so fast!"

However, if you think about it carefully, it makes sense.

A new drug usually takes 12.5 years from research and development to launch without fraud.

The cost of funds ranges from 20 billion to tens of billions, and the unit is US dollars.

The success rate is only about 10%.

The approval of each new drug project is the most important decision for a company and requires a large amount of data to support research.

In particular, research on patents, documents, and regulations requires a lot of time.

Judging from the current situation, Huirui took shortcuts in order to obtain new drugs faster.

"Is it exactly the same?" Chang Le asked.

"I asked Zhang Jingfang. She analyzed Huirui Jaxlovid." Zeng Xi said:

"She told me that what is certain is that Huirui violated the two core technologies of "Guanke"..."

"Delivery Systems and Nucleoside Modification Technologies."

"Guanke" therapy uses advanced synthetic mRNA technology.

Synthetic mRNA technology is very difficult, and the difficulty lies in two aspects.

One is that mRNA is not as stable as DNA.

It breaks down rapidly in the body, making it difficult to deliver the mRNA to the right location in the right cell.

In most processes, the mRNA is broken down during delivery.

Second, once synthetic mRNA is delivered into the body, it will trigger an excessive immune response and cause serious consequences to the patient.

"I haven't heard of the side effects of Jaxlovid, so they copied it directly?" Chang Le asked curiously.

"I also asked Zhang Jingfang about this, and she said that they basically copied the delivery system of Guanqi, and also copied part of the nucleoside modification technology..." Zeng Xi said.

To achieve stable delivery of mRNA, it is necessary to cooperate with nucleoside modification technology so that it does not trigger an immune response, and at the same time, patented technology is used to prevent the mRNA from being broken down.

"Partially? In other words, they made modifications on their own?" Chang Le continued to ask.

"Yes, in order not to be too straightforward, they made adjustments in modifying the mRNA nucleosides without authorization." Zeng Xi said.

"Will this cause unknown side effects?" Chang Le was even more curious.

"Zhang Jingfang believes that this possibility cannot be ruled out. Biotechnology is very sophisticated and complex, and small changes may bring completely different consequences." Zeng Xi said.

Chang Le nodded: "Then let's sue first. At least in Europe, we can't let them take advantage like this."

"North America...forget it, let's try our best."

Zeng Xi said: "Okay, I will contact the cooperative law firm immediately."

end of June.

Amid the COVID-19 epidemic, the Pingtouge Research Institute, which has shone brightly and attracted worldwide attention, commissioned multiple law firms to sue Huirui simultaneously in Europe and North America.

It accused the latter of infringing on the technology patent of "Guanke" and required the latter to pay its royalties.

Royalties are determined based on sales volume.

North America, for well-known reasons, is basically Hui Rui’s private territory.

It has been on the market for just over a month, and with official endorsement and full coverage, sales have reached US$15 billion.

No country in Europe has approved it for emergency use.

However, Hui Rui has already submitted the information application, and if there is no external force, it may be approved.

The move of Pingtou Ge Research Institute was to cut off Hui Rui's hand.

Faced with the accusation from Pingtou Ge Research Institute, Hui Rui hurriedly denied it.

They believe that Jaxlovid's mRNA technology is completely different from that of Crown.

They emphasized that they had established the core delivery technology ten years ago and argued that the accusations made by Pingtouge Research Institute were unreasonable and invalid.

Pingtouge Research Institute quickly counterattacked, pointing out that Huirui Company’s Jaxlovid prescription information contains an obvious lipid nanoparticle delivery system.

The chemical composition and proportion of this substance are exactly the same as those of Crown.

Huirui goes on to argue that they have their own "proprietary lipid nanoparticle delivery system."

The Pingtou Ge Research Institute obviously disagrees.

In order to enhance the effectiveness of the accusation, Pingtouge Research Institute further disclosed the pharmacological experimental data of "Guanke".

Compare the delivery system data of "Crown" with the Jaxlovid delivery system...

People in the industry can tell at a glance, what a guy!

Copy it exactly!

As a result, everyone denounced Hui Rui.

Europe.

This blatant infringement triggered strong reactions from various European countries.

Germany, France, Denmark, Finland and other countries have written to the European Commission, demanding that the European Commission immediately stop approving Huirui's Jaxlovid.

Drug regulatory authorities in Italy, Poland and other countries have successively stated:

"If infringing drugs like Huirui are allowed to enter the European market, it will be the greatest desecration of research and development and technology..."

They appealed to the European Medicines Agency and relevant EU agencies, hoping to respect original research and development and technology.

The President of Serbia even said bluntly: "'Guanqi' has been proven to be a safe and effective anti-epidemic drug in our country, and the price is not expensive. There is no need for infringing drugs like Jaxlovid."

domestic.

Pharmaceutical companies have also joined forces to guide public opinion.

"Let's not talk about Jaxlovid's infringement issue. Let's first look at the consequences of Huirui's unauthorized modification of Guanke's nucleoside modification method."

"Safety of drugs, especially mRNA-type drugs, always comes first."

""Guanke" has been widely recognized and used, and has occupied all the markets it can occupy. I can't think of a market for Jaxlovid in other regions besides administratively defined North America?"

"There is no problem in introducing good drugs, but there is a problem in introducing infringing drugs."

"Haha... In the past, Hui Rui wielded the patent stick to attack other companies, but now the situation has changed."

"Where are those slaves? Why don't you speak out? Your master violated the law."

"No matter how effective Jaxlovid is, it has no use for me. Can it make me passionate? If not, bye!"

"........."

Pingtou Ge Research Institute continues to speak out through various channels.

They pointed out that Huirui not only infringed on the delivery method...

In terms of nucleoside modification, part of the content was also copied. The copying method was simple, crude, and clumsy, without any disguise.

They also emphasized that it only took Huirui two days from the release of the virus sequence to the finalization of the drug sequence.

It only took 25 days to complete the production of the first batch of clinical drugs, which is not normal.

Hui Rui was completely silent.

The final decision needs to be decided by the court, but after a heated argument, Hui Rui lost completely.